Boehringer Ingelheim Announces First International Head-to-Head Trial of Aptivus(R) (tipranavir) versus darunavir in Treatment-Experienced HIV-Positive Patients
Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...